Vnitr Lek 2016, 62(4):312-315

The effect of antihypertensive treatment on patients with diabetes depends on the values of blood pressure: a systematic survey and meta-analyses

Jiří Widimský sr
Klinika kardiologie IKEM, Praha

What was already known about these problems

before the publication of the Northern Swedish study? Hypertension is the most important risk factor for mortality and cardiovascular disease on a global scale. Patients with diabetes mellitus demonstrate an increased risk for cardiovascular disease and they often also have hypertension at the same time. Antihypertensive treatment reduces the risk of cardiovascular diseases in patients with diabetes, however an optimum value of blood pressure is a matter of debate.

What is the special contribution of the Swedish study? Antihypertensive treatment in patients with diabetes and a systolic pressure higher than 140 mm Hg brings with it a decreased risk of mortality and cardiovascular disease. Antihypertensive treatment in patients with diabetes and a systolic lower than 140 mm Hg, however, brings with it an increased risk of mortality and cardiovascular disease. The interaction between systolic pressure values before the treatment and during it is significant.

Keywords: antihypertensive treatment; diabetes mellitus; blood pressure dependence

Received: March 12, 2016; Accepted: April 5, 2016; Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. The effect of antihypertensive treatment on patients with diabetes depends on the values of blood pressure: a systematic survey and meta-analyses. Vnitr Lek. 2016;62(4):312-315.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 52: i717. Dostupné z DOI: <http://doi:10.1136/bmj.i717>. Go to original source... Go to PubMed...
    2. Cushman WC, Evans GW, Byington RP et al. [ACCORD Study Group]. Effect of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-1585. Go to original source... Go to PubMed...
    3. Dahlöf B, Sever PS, Poulter NE et al. [ASCOT Investigators]. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906. Go to original source... Go to PubMed...
    4. Filipovský J, Widimský J jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785-801. Go to PubMed...
    5. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417-2428. Go to original source... Go to PubMed...
    6. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851-860. Go to original source... Go to PubMed...
    7. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 2015; 9(1): 48-53. Go to original source... Go to PubMed...
    8. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357. Go to original source... Go to PubMed...
    9. Oxlund CS, Henriksen JE, Tarnow L et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31(10): 2094-2102. Go to original source... Go to PubMed...
    10. Patel A, MacMahon S, Chalmers J et al. [ADVANCE Collaborative Group]. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840. Go to original source... Go to PubMed...
    11. Staessen JA, Thijs L, Fagard R et al. [Systolic Hypertension in Europe (Syst-Eur) Trial Investigators]. Effects of immediate versus delayed antihypertensive therapy outcome in the Systolic Hypertension in Europe Trial. J Hypertension 2004; 22(4): 847-857. Go to original source... Go to PubMed...
    12. Widimský J. Studie SPRINT. Randomizovaná studie porovnávající intenzivní oproti standardní kontrole systolického krevního tlaku. Vnitř Lék 2016; 62(1): 44-47. Go to PubMed...
    13. [UK Prospective Diabetes Study Group]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703-713. Go to original source...
    14. Wright JT Jr, Williamson JD, Whelton PK et al. [SPRINT Research Group]. A randomized trial of intenzive versus standard blood pressure control. N Engl J Med 2015; 373(22): 2103-2116. Go to original source... Go to PubMed...
    15. Zinman B, Wanner CH, Lachin JM et al. [EMPA-REG OUTCOME]. Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-2128. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.